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Abstract
Malignant gliomas are the most aggressive primary brain tumors. Although current
treatment includes surgery and chemo/radiation therapy, life expectancy remains on the
order of 2 years. One of the features, which make these tumors incurable, is their infiltration
into normal brain tissue. This process is incompletely understood at a molecular level and
appropriate targets need to be developed. This review discusses (1) the unique struc‐
ture of the neural extracellular matrix (ECM), (2) the basis of the proliferation to migration
transition  that  initiates  the  infiltrative  process,  (3)  the  remodeling of  the  ECM by
degradation and synthesis  of  new components,  and (4)  trophic  factors  that  act  as
chemoattractants and chemorepellents for migrating cells. Finally we briefly discuss the
challenges facing the study of this complex process and future directions in attacking this
important problem in neuro-oncology.
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1. Introduction
Malignant gliomas are the most common primary tumors of the central nervous system (CNS)
accounting for over 22,000 new cases in the USA each year [1]. Glioblastoma multiforme (GBM)
is the most aggressive (WHO grade IV) glioma and is characterized histologically by high mitotic
activity leading to hypoxia and necrosis,  nuclear atypia and cellular pleomorphism, and
microvascular  proliferation due to  secretion of  pro-angiogenic  factors.  These tumors are
uniformly fatal with standard treatment consisting of maximal surgical resection followed by
radiation and chemotherapy which targets cell proliferation (Temozolomide or other DNA
modifying agents) [2] or angiogenesis (Bevacizumab) [3], as well as other newly developed
methods of attacking dividing tumor cells (Optune-TTF) [4].
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Gliomas differ from metastatic tumors in their ability to migrate into the surrounding brain
parenchyma. While most recurrence occurs within 1–2 cm of the original tumor bed [5],
seemingly multifocal disease or so-called “butterfly glioma” can develop at distant sites as a
consequence of migration of cells along blood vessels and white matter tracts [6] (Figure 1).
Although they are highly infiltrative, less than 2% of gliomas spread outside the CNS,
suggesting that tumor cells are either not able to cross the basement membrane and enter the
vasculature or that they require a specific neural environment containing specific molecules
through which they can proliferate and migrate. Tumor cells switch from a proliferative to a
migratory or mesenchymal phenotype, resorting to this more primitive state, which mimics
the behavior of their migratory progenitors such as the radial glia that traversed white matter
pathways and other structures during embryonic development [7]. The molecular mechanisms
of this transition are currently poorly understood.
Figure 1. Butterfly glioma in a patient with bihemispheric spread due to involvement of the corpus callosum.
In this chapter, we discuss the composition of the brain’s extracellular matrix, as well as the
mechanisms by which tumor cells transition to a migratory phenotype and remodel the ECM
through degradation by novel proteases and their inhibitors. We discuss the search for ECM
molecules expressed by the tumor cells, which then respond to chemoattractants in the
environment in order to direct growth. Finally, we discuss potential targets of anti-infiltrative
therapy and the obstacles that must yet be overcome to address this important neuro-oncologic
problem.
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2. The Extracellular Matrix
The ECM consists of three components: (1) perineural nets (PN) which surround neural cells
and their processes and provide support and regulate plasticity, (2) a complex interstitial
matrix between cells, and (3) basement membranes that surround blood vessels made up
primarily of laminin, fibronectin, and collagens. ECM components are secreted by resident
cells and serve to provide structural cell support, regulate cell-cell connectivity and commu‐
nication, and sequester growth factors and chemoattractants to regulate cell motility. The
composition of the ECM varies from tissue to tissue and is comprised of proteoglycans such
as chondroitin sulfate, heparin sulfate, keratin sulfate, and a lattice of interconnected fibrous
proteins [8].
The neural extracellular matrix comprises 10–20% by volume of the brain and spinal cord and
is structurally and functionally distinct from the ECM in other tissues [9] (Figure 2). The most
abundant component of the neural ECM is hyaluronan (HA) and its associated glycoproteins.
HA is a large hygroscopic glycosaminoglycan composed of alternating D-glucuronic acid and
N-acetylglucosamine which is synthesized by hyaluronan synthase anchored to cell mem‐
branes [10]. In the developing brain, HA is organized into fiber-like structures along which
neural precursors migrate. HA is anchored to astrocytes through its receptor, CD44, a
transmembrane glycoprotein that couples the ECM to the actin cytoskeleton [11] and to
hyaluronan synthase on neurons. Overexpression of CD44 was shown to increase the length
of filopodia of neuroblastoma cells in vitro and promote invasion into a HA-rich matrix,
demonstrating how overexpression of this single gene can affect the complex sequence of
events for an invading cell to detach from its substrate, adhere to and degrade the surround‐
ing matrix, and migrate through it [12].
Figure 2. Structure of neural extracellular matrix (ECM). Reproduced with permission from Miyata et al. [14].
HA is associated with a number of proteins that are organized into a scaffold within the ECM.
The major group is chondroitin sulfate proteoglycans (CSPGs) whose structure consists of a
core protein covalently linked to chondroitin sulfate glycosaminoglycan (CS-GAG) through
serine residues [13, 14]. Chondroitin sulfate is a disaccharide chain consisting of glucuronic
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acid and N-acetylgalactosamine linked via a β-glycosidic bond and is polymerized into chains
through the activity of chondroitin synthase and polymerizing factor [15]. Variability within
CSPG derives from variation within the core protein of CSPGs as well as the number and
Figure 3. Chondroitin sulfate proteoglycan structure. (A) Binding of glycosaminoglycan side chains to core protein
through serine residues (Xyl, xylose; Gal, galactose). Sulfate groups added at R. (B) CSPG core protein with N-terminal
hyaluronan binding domain and a C-terminal tenascin-binding domain. Central domain binds GAG side chains. (C)
Structure of Lecticans (Reproduced with permission from Miyata et al. [14]).
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positions of sulfate groups, which are added via chondroitin sulfotransferases [16, 17]. This
variability determines the CSPG binding properties and their function. Link proteins such as
Bral-1 and 2, [18], Crtl1 [19], and HAPLN1 [20] stabilize the interaction between HA and CSPG
within the PN. Mice lacking Crtl1 have attenuated PN and persistent plasticity in the visual
cortex [21].
The classes of CSPG include (1) lecticans such as aggrecan, brevican, neurocan, and versican
[22], (2) phosphacan (a tyrosine phosphatase) [23], and (3) small leucine-rich proteoglycans
[24]. CSPG can be associated with the plasma membrane through a membrane-spanning
domain [25] or a GPI-anchor [26], or can be secreted into the ECM (e.g., lecticans and phos‐
phacan). In the CNS, the chondroitin sulfate side chains act as chemorepellents, and CPSGs
are known to inhibit axon projection and cell motility and limit neural plasticity [27]. The
lecticans are the principal CSPGs in the CNS, whose core proteins consist of an N-terminal
HA-binding domain and a C-terminal domain that binds tenascin-R [28] and tenascin-C [29]
(Figure 3).
The tenascin family of glycoproteins has four members, tenascin-R, -C, -X, and -W, which are
encoded by four genes with a number of splice variants [30] and are believed to modulate cell
adhesion and migration. Tenascin-R (formerly called restrictin) is found exclusively in the
adult CNS and forms trimers which crosslink CSPGs. Tenascin-R inhibits adhesion of neural
cells to fibronectin [31]. Tenascin-C is expressed during embryonic development by migrat‐
ing neural crest cells, is re-expressed during wound healing and in gliomas, and is thought to
be involved with increasing glioma cell proliferation and migration [32]. In tenascin-C
knockout mice, CSPGs aggregate and fewer PN form [33]. Tenasacin-X is not found in the
nervous system. Tenascin-W is expressed in blood vessels within gliomas and may be involved
in angiogenesis [34].
The interstitial ECM forms a highly compressible network of HA and CSPG filaments that is
resistant to cell migration by virtue of the inhibitory actions of CPSG, especially their CS
components, paucity of anchorage points in the water-rich environment, and the presence of
sequestered inhibitory molecules such as slits [35], semaphorins [36], and netrins [37].
In contrast to the hydrated PN that surrounds neurons and the loose interstitial matrix of the
brain parenchyma, the ECM around the brain's vasculature and subpial surfaces forms a more
rigid basal lamina that contains laminin, fibronectin, and type IV and VI collagens and is similar
to the ECM in other tissues [35]. This substrate is more likely to allow adhesion of migrating
cells and for this reason, gliomas tend to follow blood vessels and subpial surfaces as they
invade into the surrounding tissue [36]. They do not, however, degrade the basal lamina and
thus do not generally intravasate and spread hematogenously to distant sites.
3. Migration vs. proliferation
One of the characteristics of malignant gliomas that makes them universally fatal is their ability
to infiltrate normal brain parenchyma. This diffuse spread makes surgical cure impossible and
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makes treatment with radiation and chemotherapy difficult and inefficient. The rapid
proliferation of cells in malignant gliomas changes the tumor microenvironment, which
becomes hypoxic, acidic, and devoid of glucose and other nutrients. Tumor cells must adapt
to these changes to survive and thus change from a proliferative to a migratory phenotype in
order to reach a more favorable environment. The mechanism by which tumor cells transi‐
tion to this migratory state and the factors which trigger this process are therefore important
to understand as it serves as an excellent target for therapy. This complex metabolic change,
sometimes called the “epithelial-mesenchymal transition,” is poorly understood, however,
and involves multiple signal transduction pathways with many molecules needed to effect the
changes in gene expression needed to bring about this transition.
One of the key molecules involved with sensing stress in a cell's microenvironment is the AMP-
activated serine/threonine protein kinase (AMPK) [37]. AMPK is activated by a high AMP/ATP
ratio and other conditions of metabolic stress and causes cells to conserve energy, thus
regulating their cellular homeostasis in response to environmental cues. AMPK is activated in
response to environmental stress through phosphorylation by three known protein kinases:
liver kinase-B1 (LKB1) and the two calmodulin-dependent protein kinases, CaMKKα and
CaMKKβ, that phosphorylate AMPK in response to high intracellular calcium levels [38]. Once
activated, AMPK exerts its effects on cellular metabolism through many downstream
molecules, one of which is cyclooxygenase-2 (COX2), whose inhibition by AMPK leads to more
aggressive tumor growth and invasion [39]. Overexpression of COX2 has been seen in many
types of cancer including colon, breast, and lung [40].
LKB1, a tumor suppressor gene, is constitutively active and is the primary AMPK kinase. Its
phosphorylation of AMPK sets off a cascade that results in liberation of intracellular ATP and
conservation of energy through regulation of biosynthetic pathways [41]. Mutations in LKB1
are found in Peutz-Jeghers syndrome [42] as well as melanoma [43], lung [44], and pancreat‐
ic cancers [45]. LKB1 signaling pathways also are involved in cell migration by virtue of their
control of cytoskeletal proteins involved in cell polarization and migration. LKB1 deficiency
leads to alterations in cell polarity and impaired migration of neural progenitor cells in vivo
[46], while LKB1 activation is known to inhibit cell proliferation and can affect cellular polarity,
which is essential for cell migration [47]. The latter effect is thought to be mediated, in part,
through phosphorylation of MAP/microtubule affinity regulating kinase-3 (MARK-3), which
regulates phosphorylation of microtubule-associated proteins [48] and phosphorylation of
myosin light chain-2 directly by AMPK [49].
While the activation of AMPK leads to energy conservation in nutrient-poor environments,
the mammalian target of rapamycin complex-1 (mTORC1) is a serine/threonine kinase, which
promotes cell growth and proliferation. Inhibition of apoptosis [50] by mTOR overactivity has
been observed in several types of cancers [51]. The balance between AMPK and mTOR is
maintained in part by the tuberous sclerosis complex-2 gene (TSC-2), which is activated by
AMPK and which, in turn, inactivates mTOR [50] (Figure 4). In addition, AMPK directly
phosphorylates Raptor, a scaffold protein in the mTOR1 complex, resulting in direct
inactivation of mTORC1 [52]. Mammalian target of rapamycin complex-2 (mTORC2) is
considered resistant to rapamycin and is not sensitive to nutrients in the cellular
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microenvironment. It activates PKC-α and AKT to regulate the structure of the actin
cytoskeleton [53].
Figure 4. The AMPK/mTOR system. AMPK, AMP-activated serine/threonine protein kinase; CAMKK, Ca(2+)/calmo‐
dulin-dependent protein kinase kinase; COX2, cyclooxygenase-2; LKB1, liver kinase B1, mTOR, mammalian target of
rapamycin; TSC2, tuberous sclerosis-2.
In addition to intracellular energy levels, hypoxia and acidity are triggers for cells to regu‐
late their gene expression to adapt to a hostile environment. In tumors, hypoxia occurs due to
rapid cell proliferation and inadequate blood supply from aberrant blood vessels. It leads to
resistance to radiation and chemotherapy and is associated with a more aggressive disease
and a poorer outcome. Oxygen homeostasis is mediated by the hypoxia-inducible factor (HIF)
family of basic helix-loop-helix transcription factors, which consist of heterodimer of a
constitutively expressed beta-subunit and an alpha-subunit which, when translated, is only
stabilized under hypoxic conditions and is degraded once hypoxia has been corrected [54–56].
HIF-1 induces expression of dozens of target genes involved in the regulation of angiogene‐
sis, cellular metabolism, and cell migration by binding to hypoxia-responsive elements
(HREs) in their promoters. HIF-1α directly activates transcription of vascular endothelial
growth factor (VEGF) [57, 58], which is the major regulator of angiogenesis and directs new
blood vessel growth into hypoxic areas. HIF-2α knockdown leads to reduced levels of VEGF
and poorly vascularized, highly necrotic tumors in neuroblastoma [59]. In order to adapt to
hypoxia, cells switch from aerobic to anaerobic metabolism, and this shift is regulated, in part,
by HIF-1. Glycolytic enzymes such as pyruvate kinase M2, phosphoglycerate kinase, and
aldolase are induced by HIF-1 [60, 61] as are the glucose transporters, GLUT-1 and GLUT-3
[62]. Additionally, pyruvate dehydrogenase kinase-1 is activated, reducing mitochondrial
oxygen consumption by preventing pyruvate from entering the citric acid cycle [63]. Finally,
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HIF-1 is essential in the epithelial-mesenchymal transition by directly regulating the expres‐
sion of Twist, which is essential for cancer metastasis [64]. Twist is a basic helix-loop-helix
transcription factor whose expression is regulated through a number of signal transduction
pathways including Akt, Ras, and Wnt and whose expression correlates with higher tumor
grade [65]. It inhibits the E-cadherin-mediated adhesion between cells, which enables tumor
cells to adopt a more motile phenotype [66]. Twist also serves as a survival factor by inhibit‐
ing p53-induced apoptosis by counteracting the effects of c-MYC in neuroblastoma [67]. HIF-1
regulates expression of a number of adhesion molecules, such as alpha- and beta-integrins and
E-cadherin [68–70], matrix metalloproteinase-2 and -9 [71, 72] as well as a number of chemo‐
kines and their receptors including c-Met and CXCR4 [73–75], suggesting how hypoxia may
play a role in triggering cell migration and digestion of the ECM.
Much remains to be elucidated regarding the molecular cascades through which cells
transition to a migratory phenotype. Rapid proliferation creates a toxic microenvironment that,
when sensed by the cell, sends a signal through the AMPK-mTORC axis or by HIF-1 and others
to effect the changes in transcription needed to bring about the transformation to a migrato‐
ry phenotype so the cell may escape to a more favorable environment. As they leave the main
tumor mass and move into the brain parenchyma which limits and inhibits their migration,
glioma cells remodel their environment by secreting degradative enzymes and novel ECM
components which attempt to recapitulate the more permissive, primitive structure of the
developing brain.
4. ECM Remodeling
4.1. Degradation
In 1946, Fisher [76] proposed that metastatic spread of tumors may be mediated by proteolytic
degradation of the ECM. Since then, several classes of intracellular and extracellular proteases,
both secreted and membrane-bound, have been identified which play roles in tumorigenesis
including cell proliferation, adhesion, migration, angiogenesis, and apoptosis. The
coordination between ECM degradation and subsequent cell adhesion to ECM components
through integrin and other receptors followed by migration is the basis of glioma infiltration
into brain parenchyma.
Lysosomal cathepsins are proteases, which are critical in removing other proteases which are
in turn critical in removing unwanted cellular and extracellular components such as colla‐
gens, fibronectin, and laminin [77], and secreted cathepsins also mediate the activity of matrix
metalloproteases (MMPs) by degrading their inhibitors TIMP-1 and TIMP-2 [78]. Cathepsin B
promoter activity and protein levels are higher in high grade gliomas than in low-grade
gliomas, and the protein is maximally expressed at the leading infiltrating edge of enlarging
tumors [79]. Additionally, upregulation of cathepsins B and D has been shown to correlate
with glioma tumor grade and invasiveness [80, 81], while inhibition inhibits glioma cell
invasion in vitro [82]. Another class of intracellular proteases is the caspases, a family of
intracellular cysteine proteases essential for apoptosis that are synthesized as inactive pro-
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caspases and activated by pro-apoptotic signals [83]. Malignant cells have the ability to escape
apoptosis and, in neuroblastoma cells, the caspase 8 gene (CASP8) has been shown to be either
deleted or silenced [84]. Loss of CASP8 correlates with increased risk of metastasis in pa‐
tients with neuroblastoma. Other caspases, including CASP10, 3, 5, 6, and 7, have also found
to be mutated in various tumor types [85–89].
Extracellular proteases are secreted by migrating tumor cells in order to degrade ECM
components and to release chemoattractant and chemorepellent molecules to direct further
tumor cell migration [90]. MMPs are a class of 28 zinc-dependent endopeptidases whose
expression by tumor cells has been linked to increased invasion, proliferation, angiogenesis,
and morbidity [91]. There are both membrane-bound MMPs and secreted forms which are
released as inactive zymogens in response to growth factors such as platelet-derived growth
factor (PDGF), epidermal growth factor (EGF), and transforming growth factor beta (TGF-β)
[92], as well as in response to cell–cell and cell–ECM interactions and signaling [93]. These
inactive proenzymes contain a pro-peptide residue at the N-terminus, which masks the zinc
ion within the catalytic region. Proteolytic cleavage of this region exposes the catalytic domain
and activates the enzyme [94]. MMP2 and MMP9 are both expressed in human glioma cells in
vitro [95, 96] and overexpression in gliomas correlates with higher tumor grade and poorer
prognosis [97]. The MMPs localize to the leading edges of migrating cells, and many compo‐
nents of the neural ECM have been identified as substrates for MMP2 and MMP9 including
the lecticans-aggrecan [98], versican [99], brevican [100], and neurocan, as well as link protein
and tenascin [101] and components of the vascular basement membrane such as laminin,
fibronectin, and collagen [102]. Although these substrates have been demonstrated in vitro, the
exact role of MMP in vivo is unclear. Versican, for example, appears not be a major MMP
substrate in vivo, and glioma cells do not degrade the basal laminae of blood vessels to enter
the bloodstream. MMP activity is tightly regulated at the level of transcription, activation of
the zymogen, and by activity of tissue inhibitors of metalloproteases (TIMS) [103]; the degree
of ECM digestion during migration is clearly a complex and carefully regulated process. MMPs
are also involved in the “pro-angiogenic switch” that stimulates the production of new blood
vessels into the growing tumor mass [104], a process mediated, in large part, by the VEGF
signaling pathway [105]. The transmembrane metalloprotease, MT1-MMP, can directly
degrade the ECM and also activate pro-MMP2 and upregulate VEGF expression [106],
suggesting that this MMP may play a major role in tumor invasiveness and angiogenesis and
may serve as a potential target for therapy.
Another class of zinc-dependent metalloproteases is the ADAMS (a disintegrin and metallo‐
proteinase) and the related ADAMTS (a disintegrin and metalloproteinase with thrombo‐
spondin motifs). ADAMS are membrane-bound, zinc-dependent metalloproteases that
contain a pro-domain which is cleaved to activate the metalloprotease, a disintegrin domain
which can bind to integrin receptors, a cysteine-rich domain, an EGF-like domain, and a
transmembrane domain at the C terminus [107] (Figure 5). ADAMTS are extracellular
proteases similar in structure but lack the EGF and transmembrane domains and contain an
additional thrombospondin type I motif at the C terminus which may bind them to the ECM
[108]. ADAM-8 and ADAM-19 are expressed at high levels in gliomas, and its expression
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correlates with invasiveness [109]. ADAM-17 activates the EGF/phosphoinositide-3 kinase/
serine/threonine kinase signal transduction pathway under hypoxic conditions and leads to
increased tumor cell invasion [110]. ADAM-22 normally inhibits astrocyte proliferation in
normal brain via interactions between its disintegrin domain and cell surface integrins. It is
downregulated in high-grade gliomas leading to elimination of this growth inhibition [111].
ADAMTS-4 and ADAMTS-5 degrade the lectican and small leucine-rich repeat families of
proteoglycans, and their expression also correlates with glioma invasiveness [112].
Figure 5. ADAM/ADAMT structure. ADAM and ADAMT members contain a propeptide domain (Pro) followed by
the enzymatic metalloprotease domain containing the Zn-binding site followed by the disintegrin- and cystein-rich
domains. ADAM members contain an EGF-like domain and ADAMTS contain additional thrombospondin type 1 mo‐
tifs (TSP1) transmembrane (TM).
Finally, plasmin degrades ECM components and activates several MMPs, and the plasmino‐
gen activators, urokinase-type PA (uPA), expressed by glioma cells, and tissue-type PA (tPA)
transmembrane (TM) expressed in the endothelium of blood vessels, both play an important
role in tumor cell invasion and angiogenesis [113, 114]. There is a higher level of expression of
uPA in higher-grade gliomas than in lower-grade gliomas [115] and its binding to its recep‐
tor (uPAR) causes it to form a heteromeric complex with integrin receptors, which are also
highly expressed on glioma cells. These then initiate signal transduction cascades that result
in the upregulation of uPA, MMP, and other molecules that promote cell migration through
the ECM [116].
4.2. Synthesis
It is evident that intracellular and extracellular proteases play important roles in the com‐
plex process of glioma cell-cell adhesion and attachment and detachment to ECM compo‐
nents during migration. This process is mediated by a well-regulated cascade of signal
transduction pathways that also lead to the production of novel ECM components to create a
new scaffold on which tumor cells can migrate. As migrating cells degrade the ECM, they
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further change their microenvironment by secreting novel proteins and liberating peptides on
which to migrate and generating chemoattractants and chemorepellents for guidance. In many
ways, this new environment is reminiscent of that of the primitive CNS in which cell migra‐
tion was abundant in setting up the organization of the brain.
One of the earliest events in glioma formation is the loss of the p53 tumor suppressor gene and
upregulation of secreted protein acidic and rich in cysteine (SPARC), an ECM-associated
glycoprotein that has an anti-adhesive role and leads to cell rounding and detachment from
the ECM [117]. This is thought to be accomplished through the activation of P38 mitogen-
activated protein kinase (MAPK)-heat shock protein (HSP)-27, Akt, and Shc-Raf-extracellu‐
lar signal-regulated kinase (ERK) signaling pathways [118]. SPARC is secreted at the leading
edge of the invading cells [119] and has been shown to increase invasion in vitro [120] and in
vivo [121]. Additionally, the combination of SPARC overexpression and loss of p53 may play
a role in promoting cell survival by escaping immune surveillance [122]. SPARC is highly
expressed in gliomas, and increased levels are associated with poorer prognosis [123].
Interestingly, SPARC levels are higher in developing brain, where cell migration is necessa‐
ry for setting up the architecture of the developing brain, so it is not surprising that invading
glioma cells try to recapitulate this more permissive environment.
The Receptor-type protein tyrosine phosphatase mu (PTPμ) is a cell adhesion molecule
normally found in neurons and glia but is absent in higher-grade, infiltrative gliomas. It is
hypothesized to be involved with cell-cell adhesion and contact inhibition and that its loss
allows for cell migration [124]. PTPμ is cleaved in human GBM tumor tissue and cell lines by
a number of proteases including ADAMS, calpain, and serine proteases to generate protein
fragments with unique biologic functions affecting cell adhesion and migration [125]. In
addition to the degradation of the protein component of the ECM, glioma cells secrete
hyaluronidases, which break down HA in the ECM, generating soluble HA, which activates
MMP and promotes invasion [126]. Increased levels of HA and hyaluronectin are found in
peripherally invasive regions of certain tumors [127] creating a more disorganized matrix
through which cells can migrate. Receptor-type protein tyrosine phosphatase zeta (RPTP-ζ) is
a membrane-bound proteoglycan expressed in developing and adult brains as well as in
migrating glioma cells [128]. The soluble factor pleiotrophin is overexpressed in gliomas and,
through binding to RPTP-ζ, promotes cytoskeletal changes through modification of beta-
catenin, beta-adducin, and Fyn [129]. RPTP-ζ    undergoes differential splicing and one splice
variant, phosphacan, is a soluble factor lacking the cytoplasmic phosphatase domain.
Phosphacan is also highly expressed during embryogenesis and in migrating glioma cells and
may regulate glioma migration through interactions with tenascin in the ECM [130] and
axonin [131].
Two members of the lectican family, which are normally inhibitory to cell migration, versi‐
can and brevican, have unique isoforms that are present at different times of development,
and these tumor-specific isoforms have been shown to promote invasion. Versican under‐
goes differential splicing to generate four different isoforms (V0, V1, V2, and V3), which vary
in their GAG-binding domains. The V2 isoform is predominant in the adult CNS and is a potent
inhibitor of axonal growth into the ECM [132]. The V0/V1 isoform, however, is found in the
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primitive developing brain and is upregulated by TGF-β in malignant glioma [133], where it
acts as a pro-migratory factor by upregulating membrane type 1 matrix metalloprotease (MT1-
MMP) through the activation of microglial Toll-like receptor 2 (TLR2) [134]. Brevican, on the
other hand, undergoes differential glycosylation and there are novel glycoforms in gliomas in
developing and mature brain [135]. It is overexpressed in malignant gliomas, and its brevi‐
can knockdown inhibits proliferation, invasion, and spread of brevican-expressing glioma
cells in vitro [136]. Not only is brevican overexpressed in gliomas, it is also proteolytically
cleaved by metalloproteases of the ADAMTS family including ADAMTS-4 and -5, which are
also overexpressed in gliomas [137]. If this posttranslational cleavage is blocked, brevican does
not enhance glioma cell invasion in vitro or tumor progression in vivo [138].
Because the basal lamina of blood vessels presents a more favorable substrate for migration,
it is not surprising that migrating glioma cells secrete basal lamina components to travel on.
For example, certain laminin isoforms are secreted by glioma cells, and these cells interact with
these isoforms and others on the tumor vasculature through the alpha3beta1 integrin during
migration [139]. As tumor cells proliferate, the tumor mass becomes denser, and this mechan‐
ical stress induces secretion of collagens, their crosslinker LOX, and the angiogenic factor
VEGF [140]. Collagens bind to integrins via integrin-binding domains at the cell surface and
can thus activate signal transduction pathways that control proliferation, angiogenesis, and
migration [141]. Integrins are associated with the actin cytoskeleton through the interaction
with talin and with the microtubule network via paxillin and binding to components of the
cytoskeleton modulates the affinity of integrins for the ECM [142]. Glioma cells can migrate
along fibronectin in the vascular ECM, and both versican and brevican can increase synthe‐
sis of fibronectin through an EGFR-dependent mechanism by binding to β-1 integrin and β-3
integrin, respectively [143–145]. These newly synthesized fibronectin fibrils accumulate at the
migrating cell surface and serve to reorganize the ECM and promote cell attachment [146, 147].
4.3. Transcriptional control
The regulation of the expression of novel proteins in gliomas is poorly understood but is surely
a complex process involving many signal transduction pathways and transcription factors,
and some candidates have emerged that may regulate cell migration. The Oct-3/4 transcrip‐
tion factor is involved in regulating self-renewal in stem cells and was recently found to be
overexpressed in malignant gliomas. Oct-3/4 expressing-glioblastoma cells exhibited in‐
creased migration and invasion in vitro and resulted in upregulated FAK and c-Src expres‐
sion, which mediate integrin signals as well as increased MMP-13 expression [148]. ATF2,
another transcription factor expressed in malignant glioma, is thought to be involved in the
regulation of cell invasion as its level of expression is correlated with cell invasion in vitro [149].
Finally, suppressor of fused (Sufu) is a tumor suppressor which downregulates hedgehog,
WNT, and other signaling pathways to prevent tumorigenesis [150, 151]. Overexpression
suppresses glioma cell proliferation and invasiveness, angiogenesis, and in vivo tumor growth,
while knockdown of Sufu promoted these effects, possibly by directly affecting Gli1, a
transcription factor in the hedgehog signaling pathway [152].
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4.4. Chemotaxis
Once glial cells switch to a migratory phenotype, they degrade the ECM surrounding them,
detach from the matrix and extend “invadopodia”, actin-rich protrusions with ECM proteo‐
lytic activity that bind to and digest ECM components as a result of complex signal transduc‐
tion pathways linking the extracellular microenvironment to the actin cytoskeleton [153]. Cells
respond to soluble molecules in this environment and use these cues to direct migration
through various signal transduction pathways. These include growth factors, soluble pepti‐
des generated by proteolysis of cell surface adhesion molecules [118], and small chemotactic
cytokines.
The EGF family of growth factors is known to stimulate cell proliferation and migration [154],
and overexpression of EGF receptor (EGFR) is an important feature distinguishing high-grade
from low-grade gliomas [155], and the highest level of expression is found at the invasive
border of the expanding tumor [156]. EGFR is amplified in 40% of GBM and of these, half have
a mutant form of the receptor (EGFRvIII) lacking the ligand-binding domain leading to
constitutive activation [157]. Ligand binding induces dimerization and activation of EGFR, a
receptor tyrosine kinase (RTK), whose signaling results in cell proliferation, angiogenesis as
well as metastatic spread through the activation of PI3K-AKT-GSK3b-Rac1 and Ras-Raf-MEK-
ERK signal transduction pathways [158]. However, the activation of wild-type EGFR pro‐
motes invasion independent of angiogenesis, whereas loss of its activity results in angiogenic
tumor growth. EGFRvIII might only be involved in stimulating angiogenic tumor growth
when wild-type EGFR expression is lost [159,160]. Formylpeptide receptor (FPR) is a G-
protein-coupled receptor that has been shown to be expressed in highly malignant gliomas
[161]. Necrotic GBM cells release a number of potential ligands for FPR, and the activation of
this pathway promotes chemotaxis as well as the production of VEGF [162, 163]. In addition,
FPR has been shown to transactivate EGFR leading to increased chemotaxis and prolifera‐
tion [164].
Scatter factor/hepatocyte growth factor (SF/HGF) as well as its receptor which is encoded by
the c-MET proto-oncogene are both are upregulated in malignant gliomas. MET is a trans‐
membrane RTK whose signal transduction cascade leads to increased gliomas motility in vitro
as well as survival and angiogenesis [165]. Fibroblast growth factor (FGF) may act synergisti‐
cally with upregulated VEGF and SF/HGF in GBM cells to enhance malignancy [166].
Serine-threonine kinases also play a role in tumorigenesis. TGF-β is an important growth factor
whose signaling is involved in invasion as well as proliferation and survival of glioma cells
[167]. Its receptor is a serine-threonine kinase that, on ligand binding, oligomerizes and
activates a signal transduction cascade that results in the translocation of activated Smads to
the nucleus where they interact with other transcription factors to regulate expression of genes
involved in cell motility and proliferation [168]. TGF-β signaling upregulates MMP expres‐
sion and suppresses tissue inhibitors of metalloproteinase (TIMP), thus promoting invasion
[169] and inhibition of TGF-β1 or knockdown of its receptor reduces invasiveness in vitro [170].
Chemotactic cytokines are a group of small molecules that have been found to regulate the
migration of leukocytes in the immune system and have been found to be involved in
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metastatic behavior of certain cancers [171]. Chemokine receptors are G-protein-coupled
transmembrane receptors whose signaling pathways regulate many cellular activities
including motility. Chemokines and their receptors are expressed throughout the CNS by
neurons and glia and are overexpressed in high-grade gliomas [172]. Stromal-derived factor
1 (SDF-1) also called CXCL2 is a chemotactic cytokine, which, along with its receptor CXCR4,
is overexpressed in gliomas as well as within the vascular endothelium along the hypoxic rim
of the tumor [173, 174]. SDF-1 has been shown to promote the migration of glioma cells in vitro
[175] by upregulating the expression of membrane type-2 matrix metalloproteinase (MT2-
MMP) [176]. CXCL1 is another small chemokine known to be involved in the metastatic spread
in melanoma [177] and has been shown to be highly expressed in glioma samples and promotes
migration in vitro by upregulating MMP-2 and β1-integrin [178]. TGF-β signaling promotes
invasion by reducing expression of neurotactin, a chemokine also known as CX3CL1 whose
pro-adhesive properties must be overcome to allow cells to detach and migrate. The treat‐
ment of glioma cells with recombinant TGF-β1 reduced CX3CL1, expression and facilitated
glioma cell detachment and dispersion [179].
Both positive and negative signals exist within the microenvironment of glioma cells, and
hypoxia is an important chemorepellent as described previously which induces cell migra‐
tion away from the tumor mass. HIF-1α is stabilized at the leading tumor edge and mediates
cell invasion and angiogenesis through integrin and RTK signaling pathways [180]. Slit
glycoproteins are secreted into the ECM and normally serve as chemorepulsive factors but
whose expression is diminished in invasive gliomas through promoter methylation. They
normally bind to members of the Roundabout (Robo) family of transmembrane receptors and
lead to depolymerization of the actin cytoskeleton within the invadopodia to promote cell
adhesion [181, 182]. This may be accomplished through the inactivation of Cdc42, a Rho
GTPase known to be involved in cell motility [183].
Semaphorins and their receptors (plexins and neuropilins) have been found to be involved in
cell migration and metastasis as well as proliferation and angiogenesis in several types of
cancers [184–188], and different members of the family have different functions depending on
the type of tumor involved. For example, Sema 3A inhibits migration in GBM and has anti-
angiogenic properties in meningioma [189, 190]. Secreted semaphorins contain an N-termi‐
nal sema domain followed by variable numbers of PSI (plexins, semaphorins, and integrins)
and immunoglobulin-like domains in their extracellular regions [191]. Sema 3A binds to the
Neuropilin-1 receptor that recruits the PlexinA1 receptor to transduce a chemorepulsive signal.
Sema3A also binds Neuropilin-2 but at a lower affinity than Neuropilin-1, and the binding of
Neuropilin-2 acts to modulate cell signaling and converts the repulsive signal into an attractive
one. Blocking Neuropilin-1 or Plexin A1 switches the Sema3A response from repulsion to
attraction, while blockade of Neuropilin-2 suppresses Sema3A's typical chemorepulsive
effect [192]. Similarly, Sema 4D which binds to PlexinB1 and acts through Rho [193], and
Sema5A which binds to PlexinB3 and acts through Rac1, both act as chemorepellents by
ultimately affecting the actin cytoskeleton and altering cell morphology [194].
Finally, Netrins are secreted laminin-associated chemotactic molecules that regulate embry‐
onic axon migration [195] which have also been shown to be involved in glioma cell migra‐
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tion, mediated by binding to their receptors, deleted in colorectal cancer (DCC), neogenin, and
uncoordinated-5 (UNC5) [196–198]. Netrins have been shown to localize to cell surfaces and
interact with laminins in the basement membrane of blood vessels. Netrin-1 binding to DCC
receptors on migrating glia promotes the formation of focal adhesions, limiting migration.
GBMs have been shown to downregulate Netrins, thus releasing the inhibition and promot‐
ing loss of cell-cell interaction, promoting migration along basement membranes [199]. Though
Netrin-1 binding to the DCC receptor tends to promote adhesion, limiting migration, UNC5
binding transforms this to repulsion [200]. This switch from attachment to motility is remi‐
niscent of that described earlier with the semaphorins.
5. Future Directions
Current therapy for malignant gliomas is aimed at reducing tumor burden and targeting
dividing cells with cytotoxic chemotherapy, anti-angiogenic agents, or tumor-treating fields.
New agents targeting new pathways are desperately needed as survival still remains extreme‐
ly poor and glioma cells become resistant over time to current therapies. Delivering therapy
to normal brain parenchyma containing infiltrating tumor cells is also difficult as the blood-
brain barrier remains largely intact, though several strategies have been attempted to
overcome this [201]. Limiting the invasiveness of these aggressive tumors is desirable;
however, the molecular pathways involved in this complex process remain incompletely
understood and new targets and therapies are lacking. Additionally, because tumor cells seem
to adopt either a proliferative or migratory phenotype, preventing migration may impose a
selective advantage for cells to proliferate rather than migrate leading to more rapid local
recurrences. There is also no way to visualize invading cells until they stop migrating and
proliferate to create a radiographically evident tumor mass. Two-dimensional in vitro assays
have been used to study this process using glass or plastic substrates and more recently, assays
using hydrogels or nanofiber scaffolds have been developed to better simulate the three-
dimensional microenvironment encountered by migrating tumor cells [202–204].
Identifying molecular targets has been a priority in developing new therapies for GBM, and
the complex process of cell migration offers many potential targets including ECM compo‐
nents, proteases, and members of signal transduction pathways. The neural ECM has many
unique components that are potential targets for therapy. Because tenascin is upregulated in
malignant gliomas and may be a stem cell marker [205], it is an attractive target and phase I
trials are underway exploring the use of radiolabeled monoclonal antibodies to tenascin-C or
tenascin-R to deliver a radiation boost to the resection cavity. Since many signal transduc‐
tion pathways involved in glioma invasion often involve RTKs, and since various RTKs are
mutated or overexpressed in GBM, RTK inhibitors are an obvious choice of targeted therapy.
The results, however, have been disappointing, and no clear RTK inhibitor or combination has
demonstrated a significant survival benefit [206]. Similarly, several inhibitors of MMPs have
been investigated and, though some have shown efficacy in vitro, no clear clinical benefit has
yet been demonstrated [207–209]. Cilengitide is an arginine-glycine-aspartic acid containing
peptide that targets integrins and, though it was promising in preclinical studies, it failed to
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show improvement in progression-free survival or overall survival in both the CENTRIC [210]
and CORE [211] trials investigating the addition of cilengitide to standard therapy in pa‐
tients with newly diagnosed GBM with or without MGMT promoter methylation.
Many molecules involved in regulating cell migration in malignant gliomas are also in‐
volved in angiogenesis, cell proliferation, and avoidance of apoptosis; so agents targeting these
molecules would be expected to have multiple antitumor effects. However, results have been
mixed and, though in vitro data are encouraging for many agents, none has proven success‐
ful in showing clinical improvement in survival. There is apparently much redundancy in
these signaling pathways, requiring a more complete understanding of these molecular events
as well as more accurate modeling with which to study the complex processes involved in
tumor spread. The earliest events leading to a migratory phenotype would be ideal candi‐
dates for therapy, though inhibiting migration could select for a proliferating phenotype
leading to faster local recurrence. Hopefully, as we achieve a better understanding of the
genetics and molecular alterations leading to glioma invasion, new therapies will arise to limit
this aggressive, deadly disease.
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